Stifel on Repligen (RGEN) M&A Speculation with Maravai (MRVI)
Stifel analyst Daniel Arias reiterated a Buy rating and $207.00 price target on Repligen (NASDAQ: RGEN)The analyst comments "Reuters is ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)